Eisai Seeks EMA Approval for Less Frequent Leqembi Dosing
Event summary
- Eisai submitted a Marketing Authorisation Variation to the EMA for a once-every-four-week intravenous maintenance dosing regimen for Leqembi (lecanemab).
- The proposed change follows an initial dosing regimen of once every two weeks for 18 months.
- Lecanemab is currently approved in 53 countries and under regulatory review in 7 others.
- BioArctic and Eisai are preparing for joint commercialization in the Nordic region.
The big picture
Eisai's submission to the EMA for a less frequent dosing regimen for Leqembi reflects a strategic move to enhance patient convenience and potentially reduce healthcare costs. This aligns with broader industry trends towards optimizing treatment protocols for neurodegenerative diseases. The collaboration between BioArctic and Eisai underscores the importance of strategic partnerships in advancing innovative therapies for Alzheimer's disease.
What we're watching
- Regulatory Approval
- Whether the EMA will approve the less frequent dosing regimen and how this may impact patient compliance and market adoption.
- Commercial Strategy
- The pace at which BioArctic and Eisai can scale commercialization efforts in the Nordic region and other key markets.
- Competitive Dynamics
- How this regulatory submission positions Leqembi against other emerging Alzheimer's treatments in the pipeline.